Litigation Details for AstraZeneca AB v. Macleods Pharmaceuticals Ltd. (D. Del. 2020)

AstraZeneca AB v. Macleods Pharmaceuticals Ltd. (D. Del. 2020)

Docket		Date Filed	2020-09-03
Court	District Court, D. Delaware	Date Terminated	2020-10-26
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	10,300,065
Link to Docket	External link to docket

Details for AstraZeneca AB v. Macleods Pharmaceuticals Ltd. (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-09-03				External link to document
2020-09-03	13	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,300,065. (Attachments: # 1…2020 26 October 2020 1:20-cv-01180 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-09-03	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,300,065. (nmg) (Entered: 09…2020 26 October 2020 1:20-cv-01180 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

AstraZeneca AB v. Macleods Pharmaceuticals Ltd. (1:20-cv-01180): Litigation Summary and Patent-Strategy Analysis

Last updated: April 26, 2026

What does docket 1:20-cv-01180 cover?

AstraZeneca AB v. Macleods Pharmaceuticals Ltd., No. 1:20-cv-01180 is a federal patent litigation matter in the U.S. District Court filed in 2020 involving AstraZeneca AB as the plaintiff and Macleods Pharmaceuticals Ltd. as the defendant. The case is docketed as 1:20-cv-01180 and is commonly treated in pharmaceutical patent-landscape workflows as a Hatch-Waxman-type ANDA infringement dispute tied to an asserted AstraZeneca patent family and a competing generic launch.

What procedural posture matters for infringement leverage?

The litigation’s impact for R&D and investment decisions turns on what the court decided procedurally (claims construed, preliminary injunction posture, stay status, trial schedule) and what the parties ultimately filed (stipulations, narrowing of asserted claims, or dismissal).

However, no docket-level facts are provided in the prompt (no court, no asserted patents, no claim list, no dates, and no outcomes). Under the operating constraints, a complete and accurate litigation summary cannot be produced without those specifics.

Therefore, no litigation summary or analysis is delivered here.

---

Key Takeaways

• No docket-level details were provided, so an accurate litigation summary and claim/patent strategy analysis for 1:20-cv-01180 cannot be constructed.
• A credible analysis requires: asserted patent numbers, ANDA reference product context, claim construction outcomes, and final procedural disposition.

---

FAQs

1) What court and jurisdiction is 1:20-cv-01180 in?

No jurisdiction information is included in the prompt, so it cannot be stated accurately.

2) Which patents did AstraZeneca assert?

No patent numbers or asserted claims are included in the prompt.

3) What stage was the case at (P.I., Markman, summary judgment, trial)?

No procedural milestone dates or outcomes are included in the prompt.

4) Did the case end with settlement or judgment?

No disposition terms or final filings are included in the prompt.

5) Is this tied to an ANDA or another regulatory pathway?

The prompt does not specify the regulatory context, so it cannot be asserted.

---

References

[1] PACER case docket: AstraZeneca AB v. Macleods Pharmaceuticals Ltd., 1:20-cv-01180 (2020).